GCA
ATRC icon

Genesee Capital Advisors’s AtriCure ATRC Stock Holding History

Genesee Capital Advisors’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25,911
Closed -$1.8M – 112
2021
Q4 		$1.8M Sell
25,911
-1,655
-6% -$120K 0.86% 33
2021
Q3 		$1.92M Buy
+27,566
New +$2.12M 0.95% 35

Other funds holding ATRC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Genesee Capital Advisors's ATRC Position: Q1 2022 in Review

Genesee Capital Advisors sold out of AtriCure (ATRC) in Q1 2022, closing a stake of 25,911 shares — an estimated $1.8M sold.

Genesee Capital Advisors first reported a position in ATRC in Q3 2021 and held it in 2 quarters. The position peaked at $1.92M in Q3 2021. 217 funds tracked by Wall St. Rank hold ATRC as of Q1 2022.

  • Genesee Capital Advisors reported no remaining AtriCure position as of Q1 2022 after selling out during the quarter.
  • Genesee Capital Advisors sold 25,911 AtriCure shares in Q1 2022, an estimated $1.8M.
  • Genesee Capital Advisors first reported a position in AtriCure in Q3 2021 and held it in 2 quarters.
  • Genesee Capital Advisors's AtriCure position peaked at $1.92M in Q3 2021.
  • 217 funds tracked by Wall St. Rank held AtriCure as of Q1 2022.

Based on Genesee Capital Advisors's 13F filing for Q1 2022, filed 25 May 2022.